Analysis of Ginkgo Bioworks' Q3 results and business model, with a focus on growth, customer acquisition and cash flow ...

XWELL delivered 2024 third quarter revenue growth of approximately 13% from the comparable quarter in 2023. Additionally, for the nine-month period ended September 30, 2024, XWELL delivered revenue ...

Ginkgo Bioworks is offering its newly-completed Boston Seaport lab complex for sublease as it shrinks its real estate ...

Ginkgo Bioworks is headquartered at 27 Drydock Avenue in Boston's Seaport. Ginkgo has canceled its planned move into a ...

One of the few bright spots in Boston’s life-science lab space market this year has dimmed.

Q3 2024 Earnings Call Transcript November 12, 2024 Megan LeDuc: Good evening. I’m Megan LeDuc, Manager of Investor Relations ...

Ginkgo Bioworks reported mixed Q3, with a $45M one-time revenue boost masking underlying revenue growth issues. Read why I ...

Ginkgo Bioworks (DNA) delivered earnings and revenue surprises of 55% and 102.77%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Ginkgo Bioworks Holdings, Inc. , which is building the leading platform for cell programming and biosecurity, today announced its results for the third quarter ended September ...

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast ... Rayonier Adv Materials and Ginkgo Bioworks ...

In a report released today, Tejas Savant from Morgan Stanley maintained a Buy rating on Guardant Health (GH – Research Report), with a ...

Return on Assets (ROA): Ginkgo Bioworks Holdings's ROA lags behind industry averages, suggesting challenges in maximizing ...